In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

Swiss pharmaceutical company Roche has reported final overall survival outcomes from a long-term Phase III trial of Perjeta ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 ...

After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery ...

Black Diamond Therapeutics, Inc.’s BDTX share price has dipped by 5.39%, which has investors questioning if this is right ...

Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy121% reduction ...

Prior screening mammography is associated with earlier stage at breast cancer diagnosis and lower breast cancer mortality ...

In the recent study, Ramalingam found that people with Stage III lung cancer who had EGFR mutations had an 84% lower risk of ...

Innovent Biologics recently announced its latest 1-year results from its phase 2 clinical trial of efdamrofusp alfa, a ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

ORIC Pharmaceuticals, Inc.’s ORIC share price has dipped by 7.54%, which has investors questioning if this is right time to ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH ...